Kornimate/medical-research-clean huggingface dataset:
evaluation of the effectiveness of ischemic pre-conditioning on the morbidity and mortality of open surgery of thoracoabdominal aortic aneurysms.

Conditions: Aortic Aneurysm; Surgery

Summary: patients having a planned open surgery of thoracoabdominal aortic aneurysms and enrolled in the study will be randomized the day of the surgery in 2 groups: * arm 1 : patients with aortic clamping with pre-conditioning * arm 2 : patients with aortic clamping without pre-conditioning patients will be then followed, during 60 days after surgery.


Eligibility criteria:
inclusion criteria: 1. patient \> 18 and \<85 years old 2. patient having a planned surgery for a thoracoabdominal aortic aneurysm by direct approach, 3. patient with aortic aneurysm requiring supra-visceral aortic clamping and visceral artery reconstruction, 4. aortic aneurysmal patient with or without distal femoral circulatory assistance, 5. patient with aortic aneurysm of atheromatous or dissecting etiology, 6. woman of childbearing potential with effective contraception (estrogen-progestin or intrauterine device or tubal ligation), postmenopausal woman (≥ 12 months of amenorrhea not induced by therapy) 7. patient who read and understood the newsletter and signed the consent form 8. patient affiliated with a social security scheme exclusion criteria: 1. patient with aortic aneurysms requiring supra-visceral aortic clamping but not requiring visceral artery reconstruction (supra-visceral aortic clamping for renal aortic juxtaposition aorta), 2. patient with thoraco abdominal aortic aneurysms requiring a circulatory arrest (aortic aneurysms affecting the descending thoracic aorta or the aortic arch) 3. patient requiring emergency aortic surgery 4. patient under treatment known as interfering with pci (nicorandil or oral antidiabetic agents), 5. pregnant or lactating woman (negative result of baseline blood test) 6. participation in another interventional study within 28 days before randomization or during this study 7. person deprived of liberty by an administrative or judicial decision or person subject to a legal measure for the protection of adults, 8. patient under the protection of justice, patient under guardianship or curatorship.

Keywords: clamping pre-conditioning
neuroimaging study on the effect of transdermal buprenorphine in complex regional pain syndrome patients

Conditions: Complex Regional Pain Syndromes

Summary: in the present study, we aim to investigate the effect of buprenorphine on neuroinflammation in patients with complex regional pain syndrome, using \[11c\]-(r)-pk11195 pet.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with complex regional pain syndrome type i (budapest criteria) and persistent back pain (vas ≥ 4). 2. patients who can stop benzodiazepine treatment 2 weeks before study 3. patients who initially decided to use buprenorphine according to clinical judgment 4. patients who are able to understand the purpose and procedure of the study exclusion criteria: 1. patients with an impaired cognitive function such as psychosis, dementia, or mental retardation 2. patients with neurologic disease, cerebrovascular disease, history of brain tumor, history of severe head trauma, history of convulsive disease 3. patients with cardiovascular disease, liver, respiratory or renal dysfunction 4. patients with biliary disease 5. patients who could not undergo the pet/magnetic resonance imaging (mri) process. 6. patients who have a risk of suicide or show aggressive behavior 7. patients who have drug dependence (dsm-iv criteria) or history (past 6 months or older) 8. employees of researchers or clinical research institutes 9. patients with hypersensitivity or contraindication to buprenorphine
mra and abr as early predictors of bilirubin-induced neurologic dysfunction in full-term jaundiced neonates

Conditions: Neonatal Hyperbilirubinemia

Summary: the aim of the research was to define the role of mrs and abr as early predictors of bilirubin-induced neurologic dysfunction (bind) in full-term neonates who required intervention (phototherapy or exchange transfusion).

neonatal jaundice is a prevalent condition. it's typically a harmless phase that occurs as the body adjusts to bilirubin levels after birth, representing a balance between its production and elimination. when there's an increase in bilirubin production and a decrease in elimination, infants become at risk for dangerous hyperbilirubinemia, potentially leading to bilirubin encephalopathy. the range of neurological issues caused by excessive bilirubin is referred to as bilirubin-induced neurologic dysfunction. detecting this condition early is crucial to prevent irreversible brain damage. some of the neurological effects include gliosis, demyelination, and interference with glutamate uptake by astrocytes in the basal ganglia. magnetic resonance spectroscopy (mrs) is an advanced imaging technique that holds promise for identifying these metabolic changes and aiding in the diagnosis and evaluation of neonates with hyperbilirubinemia. bilirubin neurotoxicity particularly affects the auditory system, starting with the brainstem cochlear nuclei, followed by the auditory nerve. this damage can occur even without the classic signs of bilirubin encephalopathy and is known as auditory neuropathy spectrum disorder (ansd). ansd is characterized by abnormal auditory neural function, while cochlear microphonics and otoacoustic emissions remain normal. the impact on hearing can vary from subtle issues in sound processing to complete deafness. abnormal results in auditory brainstem response (abr) tests can indicate the presence of acute bilirubin encephalopathy (abe), serving as the most common and earliest sign of abe.

Eligibility criteria:
inclusion criteria: * this study included term, appropriate for gestational age (aga) neonates with pathological unconjugated hyperbilirubinemia who were candidates for intervention (intensive phototherapy versus exchange transfusion) using the american academy of pediatrics guidelines; 2004. exclusion criteria: 1. preterm neonates (less than 37 weeks). 2. clinically moderate and severe acute bilirubin encephalopathy according to modified bilirubin-induced neurologic dysfunction (bind-m) score. 3. neonates born with birth asphyxia and/or poor apgar score. 4. neonates with sepsis including cns infection. 5. neonates with family history of childhood hearing loss. 6. congenital infection. 7. chromosomal abnormalities. 8. congenital ear anomalies associated with hearing loss or brain abnormalities including craniofacial anomalies. 9. patients who were receiving ototoxic drugs as aminoglycosides. 10. conjugated hyperbilirubinemia.
the effect of exercise training on quality of life and disease progression in fibrosing interstitial lung patients

Conditions: Fibrosis, Pulmonary; Pulmonary Rehabilitation

Summary: in this study, the progression of the disease and changes in quality of life will be examined over a 1-year follow-up period in groups of patients with fibrosing interstitial lung disease who either participated in or did not participate in a pulmonary rehabilitation program. after the initial evaluation, the patients will be randomized into two groups: one serving as the control group and the other as the pulmonary rehabilitation exercise group.

patients diagnosed with fibrosing lung disease by a pulmonology specialist at yedikule chest diseases and thoracic surgery training and research hospital will be included in the study. those meeting the inclusion criteria will be randomized into two groups: the exercise group (egr) and the control group (cgr). after the initial evaluation, patients will be assessed at 3, 6, and 12 months. they will be called back to the hospital for follow-up evaluations. in addition to standard medical treatment, the egr will undergo an exercise program. the initial exercise training will be conducted in the hospital, followed by online exercise sessions via video conferencing three times a week during the first week. from the second week onwards, they will be asked to perform their exercises at home three times a week using provided exercise videos and will be monitored for one year. compliance with the exercise regimen will be assessed through a weekly survey shared in a whatsapp group established for the exercise group patients. patients in the cgr will receive an information brochure containing medical treatment and physical activity recommendations

Eligibility criteria:
inclusion criteria: * aged between 18-75 years * diagnosed with fibrosing interstitial lung disease according to the clinical diagnostic criteria of the american thoracic society and european respiratory society (ats-ers) * presence of dyspnea on exertion * stable clinical condition at the time of inclusion without infection or exacerbation in the previous 4 weeks * proficiency in using a smartphone exclusion criteria: * severe comorbid diseases, unstable coronary artery disease, collagen vascular diseases, or requiring high-flow oxygen therapy (\> 3-4 l/min) * history of exertional syncope or any comorbidity that prevents exercise training (such as severe orthopedic or neurological deficits or unstable heart disease) * participation in a pulmonary rehabilitation program within the last 12 months

Keywords: ild fibrosis exercise pulmonary rehabilitation
safety and performance of a silicone implant for fecal incontinence treatment (simplyfi)

Conditions: Fecal Incontinence

Summary: the purpose of the clinical investigation is to verify that the device under investigation (simplyfi) is appropriate to significantly improve fecal incontinence in patients in whom its use is indicated.


Eligibility criteria:
inclusion criteria: * both male and female subjects * age ≥ 18 years, \<85 years * subject has failed standard conservative therapy for fecal incontinence (at least 6 months) * subject is a surgical candidate * subject is willing and able to cooperate with follow-up examinations * subject has been informed of the study procedures and the treatment and has signed an informed consent form and provided authorization to use and disclose information for research purposes. exclusion criteria: * treatment with another investigational drug or investigational device * unable to understand study requirements or is unable to comply with follow-up schedule * contraindicated according to the instruction for use of the device * pregnancy or nursing, or plans to become pregnant * history of significant obstructed defecation or other significant chronic defecatory motility disorders * current, external full thickness rectal prolapse or vaginal prolapse * inflammatory bowel disease * irritable bowel syndrome * systemic disease as source of fi (scleroderma, neurologic disorders, crohn's) * active pelvic infection * chronic diarrhea * medical history of anal, rectal, or colon cancer * prior anterior resection of the rectum * medical history of pelvic radiation therapy * significant scarring of the recto-vaginal septum, a permanent implant in the rectovaginal septum, or a history of recto-vaginal fistula * previous anorectal posterior compartment surgery * history of complex anal fistula

Keywords: surgical treatment implant
efficacy and safety of intranasal morphine for pain after third molar extraction

Conditions: Post-Operative Pain; Third Molar Extraction

Summary: this study involves approximately 200 patients designed to evaluate the efficacy and safety of intranasal (in) morphine 7.5 mg and 15 mg, intravenous morphine (iv) 7.5 mg, immediate release oral (po) morphine 60 mg or placebo in patients with acute postsurgical pain following third molar extraction.

diagnosis and main criteria for inclusion: dental outpatients undergoing the removal of 3 or more third molars (2 of which were required to be mandibular and both must be bony impacted third molars).

Eligibility criteria:
inclusion criteria: * male or female 18-40 years of age * surgical extraction of at least three or more third molars (two must be mandibular and both must be bony impacted third molars) * moderate or severe pain within 6 hours of completion of surgery exclusion criteria: * other oral surgical procedures during the same session except the removal of supernumerary third molars * evidence of nasal congestion, nasal polyps, mucosal lesions of the nostrils, postnasal drip of any etiology or any clinically significant nasal pathology that may affect the absorption of study medication or the assessment of safety * chronic respiratory insufficiency such that treatment with an opioid analgesic is contraindicated * allergy to shellfish additional inclusion/exclusion criteria may apply

Keywords: post operative pain third molar extraction dental surgery morphine
determination of the duration of the dual antiplatelet therapy by the degree of the coverage of the struts on optical coherence tomography from the randomized comparison between everolimus-eluting stents versus biolimus a9-eluting stents

Conditions: Coronary Artery Disease

Summary: this study is a retrospective and prospective follow-up study of patients who were participating in a randomized comparative study (detect-oct trial) to determine the duration of dual antiplatelet therapy for neointimal hyperplasia after biolimus stent and everolimus stent insertion . the primary objective of this study was to determine the duration of double antiplatelet therapy (dapt) based on oct results at 3 months after percutaneous coronary intervention with oct guide and percutaneous coronary intervention with guided angiography. after that, patients who were enrolled in the previous detect-oct study will be followed up for a 10 years follow-up.

this clinical trial will be followed for a long time until the 5th and 10th years of patients who have been registered for the detect-oct study to assess the patient's status at 5- and 10-year, follow-up visits are scheduled at the outpatient visit if they are currently followed-up at the registry. however, if there is no follow-up observation at the current registrar, we will follow-up the telephone survey and visit as much as possible. patients who have already passed the 5-year follow-up period from january 2, 2013, the first time to register, will be followed up by medical records to confirm the progress. to track the progress to the 10-year follow-up, we will conduct prospective observations by telephone survey.

Eligibility criteria:
inclusion criteria: * 1. patients who were enrolled in the previous detect-oct study * 2. patients who agreed with informed consents exclusion criteria: * 1. patients who disagreed with informed consents

Keywords: dual antiplatelet therapy duration optical coherence tomography
prevalence of metabolic liver diseases in patients with type 1 diabetes mellitus

Conditions: Non-alcoholic Fatty Liver Disease; Glycogen Hepatopathy; Type 1 Diabetes; Liver Diseases

Summary: nonalcoholic fatty liver disease (nafld) has been extensively studied in the context of type 2 diabetes mellitus (t2d) due to its higher prevalence and its association with obesity and syndrome metabolic, a well-established risk factor for nafld. although several studies have reported the accumulation of liver fat in patients with type 1 diabetes mellitus (t1d), the prevalence, etiology, and the consequences of nafld in patients with t1d are poorly characterized, requiring more studies in this field. in addition, liver involvement at the metabolic level in patients with t1d raises the differential diagnosis between nafld and glycogen hepatopathy (gh), a rare complication associated with the poorly metabolic control of diabetes and probably underdiagnosed, since the ultrasound pattern is the same than the nafld. the investigators have designed a cross-sectional observational study with the objective of describing the prevalence of metabolic liver diseases (nafld and gh) in the population of patients with t1d in the healthcare area of hospital del mar and hospital de vilafranca, as well as studying the relationship of these pathologies with the degree of metabolic control, the presence of metabolic syndrome and the presence of micro and macrovascular complications.


Eligibility criteria:
inclusion criteria: * men and women aged ≥ 18 years. * diagnosed with t1d of at least 6 months of evolution. * patients who give their informed consent in writing. exclusion criteria: * active alcoholism\> 30 g / day in men and\> 20 g / day in women. * known non-metabolic liver disease: alcoholic hepatitis, viral hepatitis from hbv infection and / or hcv, hemochromatosis, wilson's disease, α-1 antitrypsin deficiency, autoimmune hepatitis, hepatic granulomatous (tuberculosis, mycobacteria, histoplasmosis), hepatic lymphoma, primary neoplasia liver, liver metastasis. * active treatment with hepatotoxic drugs: amiodarone, isoniazid, rifampicin, sulfa drugs, tetracyclines, amoxycline / clavulanate, ketoconazole, methotrexate, valproic acid, trazodone, tamoxifen, methyldopa, reverse transcriptase inhibitors, chemotherapy, immunotherapy. * pregnant women. * acute decompensation of t1d (ketoacidosis) in the 3 months prior to inclusion. the inclusion after this period.
efficacy and safety of vildagliptin compared to placebo in patients with type 2 diabetes and mild hyperglycemia

Conditions: Diabetes Mellitus, Type 2

Summary: this study is not being conducted in the united states. key long-term clinical studies have shown that people with type 2 diabetes should try to achieve overall blood glucose levels as close to normal as possible. the purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar and whose blood glucose levels are close to normal.


Eligibility criteria:
inclusion criteria: * blood glucose criteria must be met * not currently on drug therapy for type 2 diabetes * body mass index (bmi) in the range 22-45 * diagnosis of type 2 diabetes for at least 8 weeks exclusion criteria: * pregnancy or lactation * type 1 diabetes * evidence of serious diabetic complications * evidence of serious cardiovascular complications * significant laboratory abnormalities as defined by the protocol * other protocol-defined exclusion criteria may apply

Keywords: type 2 diabetes vildagliptin
evaluation of preclinical toxicity andtherapeutic efficacy of kandhaga rasayanam in padarthamarai

Conditions: Tinea Infections Such as Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Mannum, Tinea Barbae, Tinea Capitis Are Studied

Summary: this study is intended to find out the therapeutic efficacy of the siddha drug kandhaga rasayanam in padarthamarai ( ring worm infection )


Eligibility criteria:
inclusion criteria: * patients clinically diagnosed with tinea infection. * direct microscopy skin scraping test positive. exclusion criteria: * pregnant or nursing women. * use of other topical or oral antifungals, immunosuppressive drugs, anthelmintic drugs either currently or during 2 weeks preceeding initiation of drug trial. * allergy or hyperensitivity to any component of the drug. * clinical case of eczema, lichen planus, pityriasis versicolor, drug induced eruptions, urticaria, intertrigo, tinea ungium. * diabetic patients.

Keywords: tinea
functional tests to resolve unsolved rare diseases. rares.

Conditions: Intellectual Disability; Rubinstein-Taybi Syndrome; Cystic Fibrosis; Congenital Heart Defect; Periventricular Nodular Heterotopia; Neurodegeneration With Brain Iron Accumulation (NBIA); Albinism

Summary: rares diseases are a heterogeneous group of conditions which need important tools for diagnosis. the use of high-throughput sequencing is able to diagnose half of the patients. for the other part it is impossible to conclude due to the presence of variants of unknown significance (vous). functional analysis are needed to bring strong argument to reclassify variants as pathogenic or benign. the main objective is to evaluate the diagnosis yield of this strategy.

the main objective is the improvement of the diagnosis of rare genetic diseases. the investigator lab is expert for diagnosis of some rare diseases such as neurodevelopmental disorder, albinism, cystic fibrosis and congenital heart defect. actually with implementation of high-throughput sequencing for diagnosis, a high number of genetic variants are found and need to be interpretated. the acmg classification is used to classify variants with argument of variant frequency, predicted effect on protein and in-silico prediction. functional evidence is a strong argument to help classify vous. the investigators propose the use of rna-seq, minigene and luciferase assay for study of vous to bring argument to classify them as benign or pathogenic.

Eligibility criteria:
inclusion criteria: * minor and adult patient. * registered for the social security system. * informed consent signed by patient or parent of a minor patient. * patient affected by one of the rare diseases studied (albinism, congenital heart defect, cystic fibrosis, neurodevelopmental disease) * patient bearing variants of unknown significance (vous) exclusion criteria: * refusal to participate in research protocol. * patient under administrative supervision * pregnant or nursing women

Keywords: variant of unknown significance functional genetics translational research rnaseq gene expression regulation
the link between periodontitis, smoking and oral cancer

Conditions: Chronic Periodontitis; Oral Cancer

Summary: periodontitis is a widely prevalent disease worldwide that has serious public health consequences. its prognosis includes tooth loss and edentulism, a condition that negatively affects chewing causing functional disability; and esthetics causing social impairment. consequently, periodontitis may end up causing marked impairment of the quality of life of the affected patients, impairment of general health and increasing the dental care costs significantly. changes in the oral mucosa arise by primary products resulting from tissue breakdown due to gingivitis. it then triggers the host cells to produce proteinases that mediate loss of marginal periodontal ligaments, apical migration of the junctional epithelium and apical spread of bacterial biofilm. therefore, this research aims to identify the risk of smoking to both periodontitis and oral cancer, and the risk of periodontitis to oral cancer.


Eligibility criteria:
inclusion criteria: * patients 18 years or older. exclusion criteria: * patients with any systemic diseases. * pregnant females. * handicapped and mentally retarded patients. * patients undergoing radiotherapy. * patients having oral cancer
genetically-informed behavioral and cognitive interventions for the management of tinnitus

Conditions: Tinnitus

Summary: psychological and behavioral interventions, such as cognitive behavioral treatment (cbt) and tinnitus retraining therapy (trt), are commonly applied either alone or in combination for the management of tinnitus but selection of the intervention model remains arbitrary. our purpose is to evaluate the hypothesis that genetic markers may guide the choice of tinnitus treatment towards improved therapeutic outcomes. patients with subjective idiopathic tinnitus are assigned to either a genetically-informed cbt or trt intervention protocol based on the status of four single nucleotide polymorphisms (snps) of the dopamine and serotonin pathways, namely comt rs4680, htr2a rs7997012, htr2a rs6311, and tph2 rs4570625, that have been associated with behavioral or cognitive responses (group a), or to a conventional approach (group b) in which the choice of treatment was not directed by genotypic data. tinnitus handicap index (thi) scores of perceived tinnitus severity are recorded at the initial and at the fourth session of treatment using appropriate questionnaires.


Eligibility criteria:
inclusion criteria: * adult patients with bothersome bilateral non-pulsative tinnitus and hearing loss exclusion criteria: * no major comorbidities * no psychiatric history